Subtle Medical Named to the 2020 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups
PRNewswire — CB Insights today named Subtle Medical to the fourth annual AI 100 ranking, showcasing the 100 most promising private artificial intelligence companies in the world. Subtle Medical was recognized for its deep learning-based software solutions that enable faster and safer medical imaging, which increases workflow efficiency and improves patient experience.
“The acceptance into the CB Insights AI Top 100 list marks a tremendous milestone for Subtle Medical,” said Enhao Gong, PhD, Founder/CEO of Subtle Medical. “We have graduated from a promising start-up to a commercial company deploying software products that directly add value for patients and the centers that serve them. Through our deep learning-powered software solutions for accelerated image acquisition, hospitals and imaging centers can reap impressive efficiency gains while improving patient satisfaction. We are honored to be mentioned among this elite class of companies using AI to improve healthcare.”
Subtle Medical has successfully launched two FDA-cleared & CE Marked products, SubtlePET™ and SubtleMR™. SubtlePET allows hospitals and imaging centers to enhance images from up to 4x faster PET scans while SubtleMR uses denoising and resolution enhancement to achieve higher quality MRI scans without additional time. Both software solutions lead to an improved patient experience during imaging procedures, while boosting exam throughput and profitability. Subtle Medical recently received a NIH SBIR Grant for $1.6 million in order to continue research on SubtleGAD™, their third software product in research phase aimed at lowering gadolinium dose in contrast-enhanced MRI exams by 90%.
Current products are just the beginning of Subtle Medical’s AI solutions. The company has a long term vision of becoming a holistic solution to improve the quality and efficiency of the entire imaging workflow, and also expanding beyond clinical radiology into life sciences, pharmaceuticals, and more.
